Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zhejiang East-Asia Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:605177'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -10.12 Med: 7.87 Max: 23.1
Current: -10.12
During the past 9 years, Zhejiang East-Asia Pharmaceutical Co's highest Return-on-Tangible-Equity was 23.10%. The lowest was -10.12%. And the median was 7.87%.
SHSE:605177's Return-on-Tangible-Equity is ranked better than 68.6% of 1204
companies
in the Biotechnology industry
Industry Median: -42.15
vs SHSE:605177: -10.12
Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Zhejiang East-Asia Pharmaceutical Co Return-on-Tangible-Equity Related Terms
Zhejiang East-Asia Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang East-Asia Pharmaceutical Co Return-on-Tangible-Equity Chart
SHSE:605177 vs VRTX, REGN, MRNA: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Zhejiang East-Asia Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang East-Asia Pharmaceutical Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhejiang East-Asia Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Zhejiang East-Asia Pharmaceutical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -21.11% mean?
Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) has a Return-on-Tangible-Equity of -21.11% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors. According to the industry distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #378 out of 1204 companies in the Biotechnology industry, placing it in the top 31.4%.
Is Zhejiang East-Asia Pharmaceutical Co's Return-on-Tangible-Equity too high?
Zhejiang East-Asia Pharmaceutical Co's current Return-on-Tangible-Equity is -21.11%. Based on the distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #378 out of 1204 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zhejiang East-Asia Pharmaceutical Co has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang East-Asia Pharmaceutical Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #378 out of 1204 companies for Return-on-Tangible-Equity. This puts Zhejiang East-Asia Pharmaceutical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors. Zhejiang East-Asia Pharmaceutical Co's current Return-on-Tangible-Equity is -21.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang East-Asia Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥19.24, compared to a current price of ¥24.73 — trading 28.5% above its estimated fair value. The current Return-on-Tangible-Equity is -21.11%. Zhejiang East-Asia Pharmaceutical Co's overall GF Score™ is 52/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Zhejiang East-Asia Pharmaceutical Co (SHSE:605177), the current Return-on-Tangible-Equity is -21.11% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥24.73 is trading 28.5% above its estimated GF Value™ of ¥19.24.
GuruFocus considers Zhejiang East-Asia Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:605177:
Return-on-Tangible-Equity: -21.11%
GF Value™: ¥19.24 vs. price of ¥24.73 (28.5% above fair value)
No single metric tells the full story. See the SHSE:605177 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.
52GF Score
Get the complete analysis for SHSE:605177
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605177 has been successfully added to your 
